Sangamo Biosciences (SGMO) Misses Q2 EPS by 4c

Sangamo Biosciences (NASDAQ: SGMO) reported Q2 EPS of ($0.17), $0.04 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $8.4 million versus the consensus estimate of $14.72 million.

For earnings history and earnings-related data on Sangamo Biosciences (SGMO) click here.

You May Also Be Interested In

• Dingdong (DDL) Misses Q1 EPS by 72c, raises guidance
• Entera Bio Ltd. (ENTX) Tops Q1 EPS by 7c
• Chicago Rivet & Machine (CVR) Reports Q1 Loss of $0.72